ACLARIS THERAPEUTICS INC
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 101
- Market Cap
- $84.9M
- Website
- http://www.aclaristx.com
Clinical Trials
37
Active:3
Completed:29
Trial Phases
4 Phases
Phase 1:5
Phase 2:24
Phase 3:6
+1 more phases
Drug Approvals
2
FDA:2
Clinical Trials
Distribution across different clinical trial phases (37 trials with phase data)• Click on a phase to view related trials
Phase 2
24 (64.9%)Phase 3
6 (16.2%)Phase 1
5 (13.5%)Phase 4
2 (5.4%)ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic DermatitisAtopicDermatitisADEczema
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT07011706
- Locations
- 🇺🇸
Aclaris Study Site, Norfolk, Virginia, United States
🇨🇦Aclaris Site, Toronto, Ontario, Canada
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06585202
- Locations
- 🇺🇸
Aclaris Investigational Site, San Antonio, Texas, United States
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05511519
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
🇺🇸Aclaris Clinical Operations, Charlotte, North Carolina, United States
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
Phase 2
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: ATI-1777 1.0% w/wDrug: VehicleDrug: ATI-1777 0.5% w/wDrug: ATI-1777 2.0% w/w
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT05432596
- Locations
- 🇺🇸
Aclaris Investigational Site, Richmond, Virginia, United States
ATI-450 Plus MTX Versus Placebo Plus MTX in Patients With Moderate to Severe Active RA
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: ATI-450 50 mg oral tablet BIDDrug: Placebo oral tabletDrug: ATI-450 20 mg oral tablet BID
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Aclaris Therapeutics, Inc.
- Target Recruit Count
- 251
- Registration Number
- NCT05279417
- Locations
- 🇵🇱
Aclaris Investigational Site, Wrocław, Poland
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Global Clinical Trials Landscape for Alopecia Universalis Reveals Growing Research Activity Across Major Pharmaceutical Companies
A comprehensive 2025 clinical trials review reveals the current global research landscape for alopecia universalis, analyzing trial distribution across regions, phases, and sponsor types.